Targeted, personalized or molecular medicine all imply maximal treatment with minimal side effects and requires definition and detection of molecular targets prior to therapy. THERANOSTICS in nuclear medicine utilizes the same vector with distinct radionuclides for diagnosis and treatment and has become innovative standard for the treatment of somatostatin receptor expressing neuroendocrine neoplasms.
No takes yet. Share an insight, caveat, or question.
Hörsch et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: